Dr. Barrientos Discusses Ibrutinib in Elderly Populations With CLL
Jacqueline C. Barrientos, MD
Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses ibrutinib (Imbruvica) in elderly populations with chronic lymphocytic leukemia (CLL).
The 3-year follow-up of the registration trial of ibrutinib in elderly patients with CLL showed promising response rates, says Barrientos, making it her go-to drug for this population.
Additionally, combinations with ibrutinib are in the pipeline, such as ibrutinib plus obinutuzumab (Gazyva).